Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | HPGD | P15428 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | UTRN | P46939 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2145238 | 1.00 | ADORA3 (0.45) | ADORA3TARBP2KDM4EALDH1A1HPGD | |
| SCHEMBL2145509 | 0.82 | ELANE (0.44) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL2145510 | 0.82 | ELANE (0.44) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL10812842 | 0.80 | TARBP2 (0.59) | ADORA3TARBP2KDM4EALDH1A1HPGD | |
| SCHEMBL10812846 | 0.80 | TARBP2 (0.59) | ADORA3TARBP2KDM4EALDH1A1HPGD | |
| SCHEMBL2790527 | 0.78 | TARBP2 (0.56) | TARBP2KDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL11171845 | 0.76 | CYP1A2 (0.45) | TARBP2KDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL9750741 | 0.75 | MAPT (0.49) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL9750592 | 0.74 | KDM4E (0.42) | TARBP2KDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL10815887 | 0.74 | MAPT (0.49) | TARBP2KMT2AMEN1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| EP-2346853-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010059606-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059606-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | ADORA3 2360/4885TARBP2 4192/4885KDM4E 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.